The experiences of patients with pulmonary. arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons

被引:11
|
作者
Hall, Heather [1 ]
Cote, Joanne [2 ]
McBean, Althea [2 ]
Purden, Margaret [1 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Sch Nursing, Ctr Nursing Res, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ H3T 1E2, Canada
来源
HEART & LUNG | 2012年 / 41卷 / 01期
关键词
Epoprostenol; Pulmonary arterial hypertension; Qualitative; Resilience; Support persons; Technology; QUALITY-OF-LIFE; RESILIENCE; THERAPY; HOME; PROSTACYCLIN;
D O I
10.1016/j.hrtlng.2011.05.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: Little is known about the day-to-day experiences of patients and their support persons during the course of epoprostenol treatment for pulmonary arterial hypertension (PAH). The study objective was to describe the experiences of patients and their support persons adjusting to PAH and continuous intravenous epoprostenol. METHODS: A qualitative descriptive design with semistructured interviews was conducted jointly with the patient and his/her support person. Seven patients and their support persons (spouse, child, friend) were included. RESULTS: Patients demonstrated personal growth and resilience as they adapted to PAH. Four patient themes emerged: initial shock, figuring it out, giving life, and ongoing struggles. Themes specific to the support person included "their life is in my hands," pressure to perform, and continuation of my role. CONCLUSION: Nurses may assist these patients and support persons by teaching technical skills, problem-solving and troubleshooting strategies, mobilizing social support, and providing opportunities to reflect on lifestyle changes and long-term adjustment to PAH. Cite this article: Hall, H., Cote, J., McBean, A., & Purden, M. (2012, JANUARY/FEBRUARY). The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons. Heart & Lung, 41(1), 35-43. doi:10.1016/j.hrtlng.2011.05.007.
引用
收藏
页码:35 / 43
页数:9
相关论文
共 50 条
  • [1] Intravenous epoprostenol therapy in the treatment of pulmonary arterial hypertension in Singapore
    Choo, Jack
    Yap, Jonathan
    Ismail, Aidila
    Hon, Jin Shing
    Ruan, Wen
    Low, Andrea
    Lim, Soo Teik
    Tan, Ju Le
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2024, 53 (10) : 627 - 631
  • [2] Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
    Kimura, Mai
    Tamura, Yuichi
    Takei, Makoto
    Yamamoto, Tsunehisa
    Ono, Tomohiko
    Kuwana, Masataka
    Fukuda, Keiichi
    Satoh, Toru
    PLOS ONE, 2015, 10 (04):
  • [3] Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol
    Rossi, Rosario
    Coppi, Francesca
    Sgura, Fabio
    Monopoli, Daniel
    Boriani, Giuseppe
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2018, 49 : 147 - 151
  • [4] Giant Fold Gastritis Induced by Epoprostenol Infusion in Patients With Pulmonary Arterial Hypertension
    Miura, Yohei
    Kataoka, Masaharu
    Chiba, Tomohiro
    Inami, Takumi
    Yoshino, Hideaki
    Satoh, Toru
    CIRCULATION JOURNAL, 2018, 82 (10) : 2676 - 2677
  • [5] Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center
    Shirai, Yuichiro
    Yasuoka, Hidekata
    Takeuchi, Tsutomu
    Satoh, Toru
    Kuwana, Masataka
    MODERN RHEUMATOLOGY, 2013, 23 (06) : 1211 - 1220
  • [6] Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension
    Simonneau, Gerald
    Rubin, Lewis J.
    Galie, Nazzareno
    Barst, Robyn J.
    Fleming, Thomas R.
    Frost, Adaani
    Engel, Peter
    Kramer, Mordechai R.
    Serdarevic-Pehar, Marjana
    Layton, Gary R.
    Sitbon, Olivier
    Badesch, David B.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (07) : 689 - 697
  • [7] Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol
    Badesch, David B.
    McGoon, Michael D.
    Barst, Robin J.
    Tapson, Victor F.
    Rubin, Lewis J.
    Wigley, Fredrick M.
    Kral, Kenneth M.
    Raphiou, Ibrahim H.
    Crater, Glenn D.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (10) : 2244 - 2249
  • [8] Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
    Timofeev, Julia
    Ruiz, George
    Fries, Melissa
    Driggers, Rita W.
    AJP REPORTS, 2013, 3 (02): : 71 - 74
  • [9] Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol
    Demerouti, Eftychia
    Karyofyllis, Panagiotis
    Manginas, Athanassios
    Anthi, Anastasia
    Karatasakis, George
    Athanassopoulos, George
    Voudris, Vassilios
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2019, 19 (02) : 99 - 105
  • [10] Low Incidence of Catheter-Related Complications in Patients With Advanced Pulmonary Arterial Hypertension Undergoing Continuous Epoprostenol Infusion
    Nagai, Toshiyuki
    Kohsaka, Shun
    Anzai, Toshihisa
    Yoshikawa, Tsutomu
    Fukuda, Keiichi
    Sato, Toru
    CHEST, 2012, 141 (01) : 272 - 273